Latest Intelligence on Medical Devices and Diagnostics in Europe

Published within

« | 1 | 2 | 3 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Zimmer: the strong get stronger

Over the past few years, Zimmer [ZMH] has demonstrated even higher growth than the impressive rates seen in the overall orthopaedic market, and is now set to become even stronger with the addition of Centerpulse. The company will take market leadership position in joint reconstruction and become the fifth largest player in the lucrative sector of spinal implants.

Published By Datamonitor
20 Oct 2003
ResearchWire
ResearchWire

UK hip implants: ceramic-on-ceramic market to remain small

Published By Datamonitor
14 Aug 2001
CommentWire
CommentWire

UK healthcare: NHS changes will have an impact - eventually

The grossly underfunded NHS is finally receiving some help. The additional funds will be used for modernization, financial incentives, paying debts, and increasing staff - all necessary steps to improve patient care. While this budget increase is only the first step in a 20-year program, any rise in NHS funding is good news for staff, patients - and medical device companies.

Published By Datamonitor
19 Apr 2002
CommentWire
CommentWire

Sulzer: paying big to save its reputation

The settlement comes nearly fifteen months after Sulzer Medica voluntarily recalled its defective acetabular hip cup. Sulzer hopes that the $200,000 compensation each patient is due to receive will enable it to move on, and the $1 billion sum will be enough to reward all affected patients. However, rebuilding its reputation will not be easy.

Published By Datamonitor
07 Feb 2002
CommentWire
CommentWire

Sulzer: hip disaster could hit rivals too

Published By Datamonitor
29 May 2001
CommentWire
CommentWire

Sulzer Medica: shareholders revolt

Sulzer Medica faces a growing revolt from investors over its latest attempt to protect its US subsidiary from obligators over the withdrawal of Inter-Op shells. Sulzer needs to answer the criticisms being voiced against it and address the uncertainty surrounding the tibial baseplate recall, or it risks losing even more investor confidence.

Published By Datamonitor
14 Nov 2001
CommentWire
CommentWire

Sulzer Medica: one year later, still fighting

A year ago, few could have expected the effects of Sulzer Medica's voluntary recall would be so serious. If individual settlements are allowed, the medical devices manufacturer is likely to go bankrupt. Even if it can negotiate a settlement, it will have to pay as much as $783 million - and then face the challenge of rebuilding its reputation.<BR />

Published By Datamonitor
14 Dec 2001
CommentWire
CommentWire

Sulzer Medica: first steps towards recovery

Published By Datamonitor
03 Sep 2001
CommentWire
CommentWire

Stents: new findings could dramatically change the market

A study has suggested that the mortality risk posed by stent thrombosis is increased five-fold for STEMI patients receiving drug-eluting stents, compared to bare-metal stents. If proven, stent development is likely to move away from new drug-coated stents allowing smaller companies a chance to compete with leading players such as Boston Scientific and Johnson & Johnson.

Published By Datamonitor
06 Sep 2007
CommentWire
CommentWire

Smith & Nephew: robot-assisted knee surgery in the future

The deal should advance S&N's position in Germany, which is Europe's largest orthopedic market and a country where robot-assisted surgery is widely accepted. The long-term benefits of the deal are less certain. While robotic techniques in orthopedics have a great deal of promise, there are still many major barriers to their global success.

Published By Datamonitor
19 Nov 2001

« | 1 | 2 | 3 | » »|

No help is available.